Clinical trials: Cerebral Amyloid Angiopathy, open to volunteers
Cerebral Amyloid Angiopathy
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy
Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society.
- Trial name
- CHN-CAA (NCT07250035)
- Testing
- Jiedu Huayu Oral Prescription
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Beijing Tiantan Hospital
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA.
- Trial name
- DIETETICA (NCT06933212)
- Testing
- Mediterranean Diet with Extra Virgin Olive Oil, Mediterranean Diet with Walnuts, Low-Fat Control Diet
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Stroke, Moyamoya Disease
Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)
The goal of this clinical trial is to obtain initial feedback on the implementation of the STRATIF-AI platform and digital twin in the secondary prevention phase in patients with stroke, Moyamoya disease and Cerebral amyloid…
- Conditions
- Stroke, Moyamoya Disease, Cerebral Amyloid Angiopathy
- Trial name
- SMART (NCT06714097)
- Testing
- AI, healthy dialogue
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy
SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
Cerebral amyloid angiopathy (CAA) is one of the major types of cerebral small vessel disease, and a leading cause of spontaneous intracerebral hemorrhage and cognitive decline in elderly patients.
- Trial name
- SENECA (NCT04204642)
- Testing
- CAA patients data collection
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy
Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy
A pre-post study will be conducted to assess whether treatment with LXB, nVNS or a combination of both interventions can enhance the clearance of Aβ in patients with CAA.
- Trial name
- Clear-Brain (NCT06421532)
- Testing
- XYWAV, gammaCore Sapphire
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Leiden University Medical Center
Cerebral Amyloid Angiopathy
A Study of AMDX-2011P in Participants With CAA
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
- Trial name
- NCT05709314
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
The goal of this clinical trial is to assess the safety and tolerability of colchicine for preventing intracerebral haemorrhage (ICH) recurrence in patients with cerebral amyloid angiopathy (CAA)-ICH at high risk of recurrence.
- Trial name
- CARE-ICH (NCT07026994)
- Testing
- Colchicine 0.5mg
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- Huashan Hospital
Cerebral Amyloid Aβ Angiopathy
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy
Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment.
- Trial name
- GENERALITY2 (NCT06864000)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease
Prognosis of Cerebral Small Vessel Disease
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients…
- Conditions
- Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease, Cadasil, CAA - Cerebral Amyloid Angiopathy
- Trial name
- PRO-SVD (NCT05734378)
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern